Company intelligence
Chiesi Group
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with more than 30 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit www.chiesi.com
Verified activity
Signals from Chiesi Group
15 published signals
Partnerships
Chiesi Group and EIR WomenTech launched the collaboration called The Impulse by Chiesi to strengthen across Finland and the Nordic countries
Reported by Fabrizio Conicella
Presence & Recognition
Chiesi Group achieved its first launch to orbit for the Isar Aerospace project.
Reported by Gabriele P.
Presence & Recognition
Chiesi Group is featured in a LinkedIn post by a German startup sending its first commercial rocket activity.
Reported by Gabriele P.
Presence & Recognition
Chiesi Group announced that the German company became the first in Europe to participate in an activity.
Reported by Gabriele P.
Presence & Recognition
Chiesi Group employee Guido D'Agostino will speak at the inaugural CPHI Sustainability Summit at Fiera Milano from 6-7 October.
Reported by Guido D'Agostino
Presence & Recognition
Chiesi Group employee Giacomo Mazzariello participated in a discussion with healthcare HR leaders from across Europe on the evolving CHRO role, succession, and readiness.
Reported by Giacomo Mazzariello
People
Chiesi Group appointed Laura Acuña Álvarez as Global Head of Medical Affairs Strategy, Fabry Disease.
Reported by Laura Acuña Álvarez
Legal & Regulatory
Chiesi Group and Oak Hill Bio Holdings received Orphan Drug Designation in Japan for its investigational drug targeting bronchopulmonary dysplasia in neonates.
Reported by Stefan Herdinius
Presence & Recognition
Chiesi Group participated in the ERSCongress2026 event in Barcelona.
Reported by Carmen Dell'Anna
Presence & Recognition
Chiesi Group held its Endo-Met POA Meeting in Charleston.
Reported by Gianna Spina
Presence & Recognition
Chiesi Group contributed to two discussions at the Economic Forum in Karpacz, moderated by Tomasz Kluszczynski, focusing on Health, Wealth and Resilience and The Air We Share.
Reported by Sandra Rose
Presence & Recognition
Chiesi Group contributed to an article highlighting initiatives involving public institutions, healthcare stakeholders, and industry working together to build a sustainable healthcare ecosystem.
Reported by Danilo Pelosi
Presence & Recognition
Chiesi Group employee Gabriele P. posted an activity on LinkedIn about entrelligence.
Reported by Gabriele P.
Presence & Recognition
Chiesi Group announced that SpaceX is busy with the Starship flight.
Reported by Gabriele P.
Presence & Recognition
Chiesi Group employee Vera Valota will be attending the ERS event in Barcelona from June 6th to August 8th.
Reported by Vera Valota (She/Her)